Stratos Wealth Partners’s Protalix BioTherapeutics PLX Stock Holding History

Stratos Wealth Partners’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.17M	Hold	500,000	–	–	0.01%	781
2026 Q1	$1.08M	Hold	500,000	–	–	0.01%	764
2025 Q4	$900K	Hold	500,000	–	–	0.01%	811
2025 Q3	$1.11M	Buy	500,000 +150,000	+43%	+$244K	0.01%	709
2025 Q2	$518K	Buy	350,000 +3,600	+1%	+$7.37K	0.01%	915
2025 Q1	$887K	Buy	346,400 +76,400	+28%	+$182K	0.01%	708
2024 Q4	$508K	Hold	270,000	–	–	0.01%	930
2024 Q3	$275K	Buy	+270,000	New	+$284K	﹤0.01%	1189

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Stratos Wealth Partners's PLX Position: Q2 2026 in Review

Stratos Wealth Partners held its Protalix BioTherapeutics (PLX) position steady in Q2 2026 at 500,000 shares worth $1.17M. The position accounts for 0.01% of the portfolio, ranked #781.

Stratos Wealth Partners first reported a position in PLX in Q3 2024 and has held it in 8 quarters since. 101 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

Stratos Wealth Partners held 500,000 shares of Protalix BioTherapeutics worth $1.17M as of Q2 2026.
Stratos Wealth Partners left its Protalix BioTherapeutics share count unchanged in Q2 2026.
Protalix BioTherapeutics made up 0.01% of Stratos Wealth Partners's portfolio in Q2 2026, its #781 holding.
Stratos Wealth Partners first reported a position in Protalix BioTherapeutics in Q3 2024 and has held it in 8 quarters since.
101 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Stratos Wealth Partners's 13F filing for Q2 2026, filed 11 Aug 2026.